Although SGLT2 inhibitors are not approved for the treatment of obesity, they can be used to treat important obesity complications specifically in patients with type 2 diabetes, HFpEF or HFrEF and chronic kidney disease. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.